GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson’s disease

Highlights • In PD, contralateral M1 showed greater beta power than ipsilateral M1. • Zolpidem reduced contralateral beta power while ipsilateral power was increased. • This resulted in a hemispheric power ratio that approached parity. • Changes were reflected in pre-movement desynchronization and p...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience 2014-12, Vol.281, p.68-76
Main Authors: Hall, S.D, Prokic, E.J, McAllister, C.J, Ronnqvist, K.C, Williams, A.C, Yamawaki, N, Witton, C, Woodhall, G.L, Stanford, I.M
Format: Article
Language:English
Subjects:
Aged
beta oscillations
Beta Rhythm - drug effects
Beta Rhythm - physiology
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Electroencephalography Phase Synchronization - drug effects
Electroencephalography Phase Synchronization - physiology
Female
GABA-A Receptor Agonists - administration & dosage
GABA-A Receptor Agonists - pharmacology
GABAA receptors
Humans
Magnetoencephalography
Male
Medical sciences
Middle Aged
Motor Cortex - drug effects
Motor Cortex - physiopathology
Nervous system (semeiology, syndromes)
Nervous system as a whole
Neurology
Parkinson Disease - physiopathology
Parkinson’s disease
primary motor cortex
Pyridines - administration & dosage
Pyridines - pharmacology
Receptors, GABA-A - drug effects
Severity of Illness Index
Zolpidem
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • In PD, contralateral M1 showed greater beta power than ipsilateral M1. • Zolpidem reduced contralateral beta power while ipsilateral power was increased. • This resulted in a hemispheric power ratio that approached parity. • Changes were reflected in pre-movement desynchronization and post-movement rebound. • These changes underlie the symptomatic improvements afforded by zolpidem.
ISSN:0306-4522
1873-7544
DOI:10.1016/j.neuroscience.2014.09.037